Public Policy Page Contents
- PSAB Documents (Statements, Reports, Testimony and Monthly Newsletters)
- Research and Development Funding for FY 2016
- Contact Congress (Legislative Action Center)
- Clinical Microbiology Resources
- Public and Scientific Affairs Board Information
- Federal and State Government Links
- Congressional Science Fellowship
Check Here for Critical Public Policy Information
- Sentinel Level Clinical Laboratory Protocols For Suspected Biological Threat Agents And Emerging Infectious Diseases
- Committee on the Status of Women in Microbiology
- Committee on Microbiological Issues Impacting Minorities
Public and Scientific Affairs Board (PSAB)
Underlying the ASM's dedication to the advancement of scientific knowledge is its commitment that science serve the public interest. To address scientific matters affecting the public interest, the ASM created the Public and Scientific Affairs Board (PSAB) in 1979. The PSAB monitors legislation and regulation and develops positions for the Society on public policy issues. The PSAB encourages the adoption of sound policies affecting science and technology and the discipline of microbiology. The PSAB responds to policy makers who may request or require an understanding of research and technology in microbiology. It also communicates microbiological issues to the public.
What's New in Public Policy?
The ASM sent a letter to Turing Pharmaceuticals regarding the company’s recent 5,000 percent cost increase for the decades old generic drug pyrimethamine (Daraprim).
The ASM sent a letter to Representatives Boustany and Thompson regarding their proposed Antibiotic and Rapid Diagnostic Research and Development Tax Credit Act of 2015. The legislation is designed to accelerate discovery of novel tools against drug resistant microbial pathogens.
The September issue of the Minority Microbiology Mentor has been published by the Committee on Microbiological Issues Impacting Minorities.
Announcement of Public Consultation on Antimicrobial Resistance Rapid, Point-of-Care Diagnostic Test Challenge
As a part of the National Strategy for Combating Antibiotic-Resistant Bacteria the U.S. Department of Health and Human Services (HHS) announced a prize competition for the delivery of one or more successful rapid point-of-care diagnostics that may be used by health care providers to identify bacterial infections.
The ASM submitted questions to the Administrator of the Centers for Medicare and Medicaid Services (CMS) on the implementation of Individualized Quality Control Plans (IQCPs) in the clinical microbiology laboratory. The answers sought will allow ASM to assist clinical microbiologists prepare for implementation of their own IQCPs by the deadline...
The September issue of the e-Public Policy Update has been published by the Office of Public Affairs.
The ASM submitted comments to the Centers for Disease Control and Prevention on the possession, use, and transfer of select agents and toxins. The comments addressed adding certain Influenza virus strains to the List of Select Agents and Toxins.
The ASM submitted comments to the National Institutes of Health (NIH) RFI on the Framework for the NIH-wide Strategic Plan. The comments will help NIH develop a 5-year strategic plan to outline a vision for biomedical research that will pursue fundamental knowledge about the nature and behavior of living systems...
August 17, 2015 - ASM Comments on Department of State and Commerce Control Regulations for Certain Pathogens
The ASM submitted comments to the US Department of Commerce and the US State Department regarding the Category XIV materials (Toxicological Agents, Including Chemical Agents, Biological Agents, and Associated Equipment) included on the United States Munitions List and the Commerce Control List.
The Department of Defense (DoD) has requested that we post the following statement to ASM members regarding the inadvertent shipment of anthrax to laboratories.